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Pharmaceutics
due to unpredictable bioavailability. A promising strategy 
to overcome these problems involves the development 
of a suitable drug colloidal carrier system. Among the 
colloidal carrier systems solid lipid nanoparticles have 
many advantages and limited disadvantages as compared 
to other colloidal carrier systems. Solid lipid nanoparticles 
(SLN) have gained attention as carriers for the preparation 
of a wide variety of poorly water soluble drugs due to 
their biodegradable and biocompatible properties and 
low toxicity.[1]
Ramipril, a potent antihypertensive agent has been used 
in the treatment of hypertensive disorders. It is a highly 
lipophillic (log p octanol/water, 3.32) and poorly water 
soluble drug, with absolute bioavailability of 28–35%.[2] 
It undergoes significant ‘first pass’ metabolism and the 
INTRODUCTION
A drug’s therapeutic efficacy depends on four fundamental 
pathways of drug transport and modification within the 
body, absorption, distribution, metabolism, and elimination. 
Failure in therapy includes insufficient drug concentration 
due to poor absorption, rapid metabolism and elimination, 
poor drug solubility, and high fluctuation of plasma levels 
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ABSTRACT
Solid lipid nanoparticles are typically spherical with an average diameter between 1 and 1000 nm. It is an 
alternative carrier system to tradition colloidal carriers, such as, emulsions, liposomes, and polymeric micro and 
nanoparticles. Ramipril is an antihypertensive agent used in the treatment of hypertension. Its oral bioavailability 
is 28% and it is rapidly excreted through the renal route. This drug has many side effects such as, postural 
hypotension, hyperkalemia, and angioedema, when given as an immediate dosage form. To overcome the 
side effects and to increase the bioavailability of ramipril, solid lipid nanoparticles of ramipril are prepared by 
using lipids (glyceryl monostearate and glyceryl monooleate) with stabilizers (tween 80, poloxamer 188, and 
span 20). The prepared formulations have been evaluated for entrapment efficiency, drug content, in-vitro 
drug release, particle size analysis, scanning electron spectroscopy, Fourier transform-infrared studies, and 
stability. A formulation containing glyceryl monooleate, stabilized with span 20 as surfactant showed prolonged 
drug release, smaller particle size, and narrow particle size distribution, as compared to other formulations with 
different surfactants and lipids.
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active metabolite of ramipril is ramiprilate. On the basis 
of the above fact, the aim of this study is to prepare and 
characterize the ramipril loaded solid lipid nanoparticles, 
using glyceryl monostearate and glyceryl monooleate as the 
lipid matrices and tween 80, poloxamer 188, and span 20, 
as stabilizers, with a view to improve the dissolution rate 
of Ramipril, which would increase the biological activities. 
Given that solid lipid nanoparticles, as an alternative 
colloidal carrier (transport) system, have the ability to 
improve the solubility/permeability of lipophilic drugs, 
they may enhance the drug absorption.[3]
MATERIALS AND METHODS
Materials
Ramipril and Poloxamer 188 were obtained as a 
gift sample from Madras Pharmaceuticals, Chennai. 
Glyceryl monostearate [GMS] (CDH Pvt. Ltd., 
Mumbai), Glyceryl monooleate [GMO] (Otto 
Chemicals, Mumbai), Polysorbate 80 (Sisco Research 
Laboratories, Chennai), Sorbitan monolaurate (Loba 
Chemie, Mumbai), Chloroform and Methanol (Rankem, 
Chennai), Dialysis Membrane 50 – LA 387 (Himedia, 
Mumbai) were purchased from the local market. All the 
reagents used were of analytical grade.
Preparation of ramipril loaded solid lipid nanoparticles
Ramipril loaded SLN were prepared by hot homogenization 
followed by the ultrasonication method.[4] Ramipril and 
monoglyceride were dissolved in a mixture of methanol 
and chloroform (1 : 1). Organic solvents were completely 
removed using a rotary flash evaporator. The embedded 
lipid layer was melted by heating to 5°C above the melting 
point of the lipid. An aqueous phase was prepared by 
dissolving the stabilizers (tween 80 or poloxamer 188 or 
span 20) in distilled water (sufficient to produce 30 ml) 
and heating to the same temperature of the oil phase. 
The hot aqueous phase was added to the oil phase and 
homogenization was performed (at 2500 rpm and 70°C) 
using a mechanical stirrer for 30 minutes. The coarse 
oil in water emulsion so obtained was sonicated using 
probe soincator for 25 minutes. Ramipril loaded SLN 
was finally obtained by allowing the hot nanoemulsion to 
cool to room temperature, and was stored at 4°C in the 
refrigerator. The composition of the different formulation 
has been given in Table 1.
In all SLN formulations the lipid concentration was kept 
constant (as 6% w/v).
Evaluation of ramipril-loaded solid lipid nanoparticles
Entrapment efficiency
The entrapment efficiency of SLN dispersion was 
determined by the centrifugation method.[5] SLN dispersion 
(containing an equivalent to 5 mg of drug) was centrifuged 
at 20000 rpm for one hour in a refrigerated centrifuge 
to collect the supernatant liquid. The collected liquid 
was filtered to measure the free drug concentration after 
suitable dilution with a fresh phosphate buffer saline 
pH 7.4. The absorbance was measured at 207 nm in a UV 
spectrophotometer[12] to calculate the entrapment efficiency 
using the following formula:
Entrapment efficiency = Wt. of drug incorporated/ 
Wt. of drug initially taken × 100
In vitro drug release
The in vitro release of ramipril from different SLN dispersions 
was determined using the dialysis bag diffusion technique.  [6] 
An accurately weighed amount of Ramipril-loaded SLN 
dispersions containing the drug equivalent to 2.5 mg was 
transferred to a dialysis bag and sealed. The sealed bag was 
then suspended in a beaker containing 250 ml of phosphate 
buffer saline pH 7.4 and stirred at a constant speed of 50 rpm 
at 37°C ± 0.5°C. Aliquots were withdrawn at predetermined 
intervals from the receptor compartment up to 12 hours 
and the same was replaced with fresh buffer. Then the 
drug content was determined spectrophotometrically by 
measuring the absorbance at 207 nm using the respective 
Table 1: Composition of ramipril loaded solid 
lipid nanoparticles containing different lipids and 
surfactants and its entrapment efficiency
Formulation Solid lipid %W/V Surfactant %W/V Entrapment 
efficiency 
% ± S.D*
F1 GMS 6 Tween 80 1.0 78.72 ± 0.64
F2 GMS 6 Tween 80 1.5 80.06 ± 0.47
F3 GMS 6 Tween 80 2.0 81.22 ± 0.52
F4 GMS 6 Poloxamer 188 1.0 81.97 ± 0.79
F5 GMS 6 Poloxamer 188 1.5 84.13 ± 0.32
F6 GMS 6 Poloxamer 188 2.0 85.70 ± 0.26
F7 GMS 6 Span 20 1.0 72.50 ± 0.79
F8 GMS 6 Span 20 1.5 74.85 ± 0.10
F9 GMS 6 Span 20 2.0 76.64 ± 0.11
F10 GMO 6 Tween 80 1.0 75.24 ± 0.05
F11 GMO 6 Tween 80 1.5 76.62 ± 0.53
F12 GMO 6 Tween 80 2.0 77.59 ± 0.18
F13 GMO 6 Poloxamer 188 1.0 79.82 ± 0.24
F14 GMO 6 Poloxamer 188 1.5 84.48 ± 0.45
F15 GMO 6 Poloxamer 188 2.0 86.40 ± 0.24
F16 GMO 6 Span 20 1.0 74.97 ± 0.32
F17 GMO 6 Span 20 1.5 79.34 ± 0.17
F18 GMO 6 Span 20 2.0 82.71 ± 0.4 4
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receptor medium as a blank, to calculate the amount of drug 
released from the nanoparticles.
Particle size analysis/scanning electron microscopy
The mean diameter of the SLNs in the dispersion was 
determined by photon correlation spectroscopy (PCS) at 
a fixed angle of 90°, at 25°C.[7] Before the measurement, 
one drop of sample was taken from each selected 
formulated nanosuspension and diluted in 10 ml of 
the dispersion medium (distilled water). The surface 
morphology of SLN was characterized by scanning 
electron microscopy.[8]
Fourier transform-infrared studies
The interaction between the lipids and drug was identified 
from the fourier transform-infrared (FT-IR) studies.[9]
Stability studies
Stability studies were carried out for the formulations 
having high entrapment efficiency by storing the 
formulations at two different temperatures, 4°C and 25 ± 
2°C[10] and the drug content was estimated every 15 days, to 
find any change in the entrapment efficiency of the SLN.
RESULTS AND DISCUSSION
Entrapment efficiency
Entrapment efficiency is an important parameter for 
characterizing solid lipid nanoparticles. In order to attain 
optimal encapsulation efficiency, several factors were 
varied, including the type and concentration of the lipid 
and surfactant material used. The entrapment efficiency of 
all the prepared SLN formulations is shown in Table 1. The 
entrapment efficiency of the SLN dispersions was found 
to be in the range of 72.50 to 86.40%.
Effect of surfactants on entrapment efficiency
All SLN formulations prepared with a higher concentration 
of surfactant (2.0%) showed higher entrapment efficiency 
[F3 - 81.22%, F6 - 85.70%, F9 - 76.64%, F12 - 77.59%, 
F15 - 86.40%, and F18 - 82.71%] irrespective of the 
type of surfactant. This showed that the increase in the 
concentration of the surfactant increased the entrapment 
efficiency. This may be due to the increase in the solubility 
of the drug in the lipid on increasing the concentration 
of the surfactant. This result was in agreement with 
the results obtained by Abdelbary et al.[7] Formulations 
containing span 20 as surfactants showed lower entrapment 
efficiency compared to the other surfactants; this could 
be due to the lower HLB value of Span 20. Hence the 
entrapment efficiency of various SLNs stabilized with 
different nonionic surfactants, and decreased in the order 
of poloxamer 188 > tween 80 > span 20.
In vitro drug release
The in vitro drug release profile of ramipril from various 
SLN formulations is shown in [Figure 1]. The in vitro release 
of ramipril from the SLN dispersion was found to be in the 
range of 54.90 to 81.40% at the end of 12 hours.
Influence of surfactants on in vitro drug release
Formulations [F3, F6 and F9] prepared by using GMS 
as a lipid matrix, with Tween 80 2.0%, Poloxamer 188 
2.0%, and Span 20 2.0% as stabilizers showed a higher 
drug release from Ramipril-loaded SLN [79.46, 81.21, and 
64.80%, respectively]. This showed that the increase in the 
concentration of the surfactant there was an increase in 
the drug release from the SLN. However, this difference 
could not be attributed to the formulations [F12, F15 and 
F18] prepared by using GMO as lipid matrix with tween 80 
2.0%, poloxamer 188 2.0%, and span 20 2.0%, respectively. 
These formulations showed a decrease in the drug release 
on the increase of the concentration of surfactant, which 
could be due to the lower melting point of the GMO than 
the GMS. The results indicated that formulation [F6 – GMS 
+ Poloxamer 188 2.0%, (81.40%)] exhibited a higher drug 
release and formulation [F18 – GMO + Span 20 2.0%, 
(54.90%)] showed a higher retarded drug release among the 
three surfactants studied. This could be due to the lower 
HLB value of Span 20 (8.6) than the other surfactants 
used as stabilizers. Thus the order of percentage of drug 
release was Poloxamer 188 > Tween 80 > Span 20 on the 
basis of the stabilizer.
Figure 1: Comparison of in vitro drug release profile of ramipril from 
various solid lipid nanoparticle formulations at the end of 12 hoursJournal of Young Pharmacists Vol 3 / No 3  219
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Influence of lipids on in vitro drug release
Formulations containing GMS as a lipid matrix exhibited 
higher drug release than the formulations containing 
GMO as the lipid matrix, which showed a more sustained 
release. GMO produced less ordered crystals than GMS, 
leading to lower drug expulsion from the imperfect lattice, 
contributing to the prolonged release of the lipophilic drug. 
Moreover, GMO was a lipid with a lower melting point 
when compared to GMS. Zur Muhlen et al.,[11] reported that 
a lower melting point could produce a controlled release 
from SLN. The order of percentage of drug release was 
Glyceryl monostearate > Glyceryl monooleate on the basis 
of the lipid matrix. Thus, it could be well concluded that the 
amount of drug released was much slower and controlled 
from the SLN dispersions prepared by using GMO as the 
lipid matrix, with Span 20 as the surfactant, than that from 
the ramipril-pure drug solution [Figure 2].
Particle size analysis
Figure 3 shows the effect of the lipid and surfactant 
concentration on the particle size distribution of ramipril-
loaded SLN prepared by using GMS and GMO with 
poloxamer 188 2.0%, tween 80 2.0%, and span 20 2.0%. 
The particle size ranged from 104 nm – 334 nm. There 
was a significant difference in the size of the particles, with 
change in the lipids.
Effect of lipids on the particle size of ramipril SLN
Ramipril-loaded solid lipid nanoparticles, prepared by 
using GMS as the lipid matrix, resulted in larger particle 
size compared to SLN prepared by using GMO as the 
lipid matrix, with all type of surfactants studied. This 
phenomenon could be attributed to the melting point 
of the lipid, GMS has a higher melting point than 
GMO, which results in a slower lipid crystallization 
from the hot homogenized condition resulting in an 
increase in the particle size. The particle size of various 
SLNs prepared with different lipids was in the order 
of GMS > GMO.
Effect of surfactants on the particle size of ramipril SLN
SLN dispersion prepared using poloxamer 188 2.0% as 
stabilizer [F6 and F15] showed lower particle size than the 
other surfactants irrespective of the lipids studied. This result 
could be explained due to the higher molecular weight of 
poloxamer 188 and higher HLB value of poloxamer 188 
when compared to tween 80 and span 20.[12] The particle 
size of various SLN, stabilized with different surfactants, 
increased in the order of Poloxamer 188 > Tween 80 > 
Span 20.
Scanning electron microscopy
SEM studies showed that the ramipril-loaded solid lipid 
nanoparticles had a spherical shape with a smooth surface 
as shown in Figure 4.
FT-IR studies
Infrared studies were carried out to confirm the compatibility 
between the lipid, drug, and selected SLN formulation. From 
the spectra it was observed that there was no major shifting, 
as well as, no loss of functional peaks between the spectra of 
Figure 4: F15 – GMO 6% + Poloxamer 188 2.0.%
Figure 2: Comparison of in vitro drug release of SLN prepared by using 
GMS 6%, GMO 6% and pure drug solution
Figure 3: Comparison of particle size of SLN of GMS 6% and GMO 
6% (PF – 68 2.0%, T – 80 2.0%, and S – 20 2.0%)
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the drug, lipid, and drug-loaded SLN. [1743.98 cm−1, 4654.04 
cm−1, 1458.18 cm−1, and 2931.34 cm−1]. This indicated no 
interaction between the drug and lipid [Figure 5].
Stability studies
The results showed that the entrapment efficiency of the 
SLN dispersion stored in 4°C was more compared to the 
SLN dispersion stored in 25°C ± 2°C. This may be due 
to more drug expulsion from the lipid matrices at higher 
temperature [Table 2].
CONCLUSION
It was observed that the hot homogenization and 
ultrasound dispersion method was a useful method 
for the successful incorporation of the poor water-
soluble drug ramipril with high entrapment efficiency. 
Furthermore, it could be presumed that if the nanometer 
range particles were obtained, the bioavailability might 
be increased. Hence, we can conclude that solid lipid 
nanoparticles provide controlled release of the drug 
and these systems are used as drug carriers for lipophilic 
drugs, to enhance the bioavailability of poorly water-
soluble drugs through nanoparticles, as a drug delivery 
system.
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Table 2: Stability studies for solid lipid nanoparticles 
(Percentage of entrapment efficiency at refrigerated 
temperature and 25∞ ± 2∞C)
Formulation Immediately after 
preparation (%)
15th day (%) 30th day (%)
4∞C 25∞±2∞C 4∞C 25∞±2∞C
F3 81.22 81.06 78.16 80.00 75.31
F6 85.70 85.06 82.90 83.94 77.91
F9 76.64 76.32 73.56 74.47 69.19
F12 77.59 77.02 74.02 75.81 70.01
F15 86.40 86.00 85.26 83.16 81.38
F18 82.71 82.15 81.86 81.57 77.69
Figure 5: Comparison of I.R spectrum of pure drug, GMO and pure 
drug + GMO